| Gemcitabine and cisplatin as neo-adjuvant for cholangiocarcinoma patients prior to liver transplantation: case-series M Abdelrahim, H Al-Rawi, A Esmail, J Xu, G Umoru, F Ibnshamsah, ... Current Oncology 29 (5), 3585-3594, 2022 | 17 | 2022 |
| Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver transplantation: an institution … M Abdelrahim, A Esmail, J Xu, G Umoru, H Al-Rawi, A Saharia, ... Frontiers in Oncology 12, 908687, 2022 | 13 | 2022 |
| Thymoquinone’s antiviral effects: it is time to be proven in the covid-19 pandemic era and its Omicron variant surge M Abdelrahim, A Esmail, N Al Saadi, E Zsigmond, E Al Najjar, D Bugazia, ... Frontiers in Pharmacology 13, 848676, 2022 | 10 | 2022 |
| P-168 Combination of gemcitabine plus cisplatin compared to non-gemcitabine and cisplatin regimens as neo-adjuvant treatment in liver transplant recipients with cholangiocarcinoma M Abdelrahim, A Esmail, J Xu, G Umoru, H Al-Rawi, A Saharia Annals of Oncology 33, S309-S310, 2022 | 4 | 2022 |
| P-169 Feasibility of gemcitabine plus cisplatin as neo-adjuvant in cholangiocarcinoma patients prior to liver transplantation A Esmail, J Xu, G Umoru, H Al-Rawi, A Saharia, M Abdelrahim Annals of Oncology 33, S310, 2022 | 4 | 2022 |
| Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation A Esmail, M Badheeb, B Alnahar, B Almiqlash, Y Sakr, B Khasawneh, ... Cancers 16 (11), 1946, 2024 | 3 | 2024 |
| Prognostic value of molecular response via ctDNA measurement in predicating response of systemic therapy in patients with advanced solid cancer. A Esmail, J Guan, J Xu, H Al-Rawi, B Parks, N Al Saadi, T Khan, ... Journal of Clinical Oncology 40 (16_suppl), e13001-e13001, 2022 | 3 | 2022 |
Maen AbdelrahimHouston Methodist Cancer Center在 houstonmethodist.org 的电子邮件经过验证
Maen AbdelrahimHouston Methodist Cancer Center在 houstonmethodist.org 的电子邮件经过验证